Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

CYRX

CryoPort Inc

Oct 23 • 04:00PM ET

6.93

Dollar change -0.32
Percentage change -4.41	%

Industrials • Integrated Freight & Logistics • USA • NASD

Peers: TMO DHR BDX CTLT STE BRKR BIO AVTR ADPT ICUI

| Held by: VTI IWM VXF IWO SCHA VTWO VHT DFAS IWN DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.67	Insider Own	3.45%	Shs Outstand	48.97M	Perf Week	-4.55%
Market Cap	342.41M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	-1.09%	Shs Float	47.71M	Perf Month	-12.83%
Income	-180.54M	PEG	-	EPS next Q	-0.32	Inst Own	107.16%	Short Float	5.52%	Perf Quarter	-22.66%
Sales	225.61M	P/S	1.52	EPS this Y	-12.76%	Inst Trans	-0.05%	Short Ratio	4.71	Perf Half Y	-57.30%
Book/sh	7.48	P/B	0.93	EPS next Y	59.02%	ROA	-18.33%	Short Interest	2.63M	Perf Year	-31.52%
Cash/sh	8.64	P/C	0.80	EPS next 5Y	-	ROE	-36.54%	52W Range	5.32 - 20.10	Perf YTD	-55.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-45.48%	ROI	-23.01%	52W High	-65.53%	Beta	1.61
Dividend TTM	-	Quick Ratio	7.99	Sales past 5Y	78.51%	Gross Margin	34.22%	52W Low	30.39%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	8.38	EPS Y/Y TTM	-282.36%	Oper. Margin	-31.92%	RSI (14)	39.30	Volatility	5.94% 6.25%
Employees	1170	Debt/Eq	1.01	Sales Y/Y TTM	-6.26%	Profit Margin	-80.03%	Recom	2.20	Target Price	12.67
Option/Short	Yes / Yes	LT Debt/Eq	0.96	EPS Q/Q	-287.89%	Payout	-	Rel Volume	0.44	Prev Close	7.25
Sales Surprise	0.07%	EPS Surprise	-308.58%	Sales Q/Q	1.01%	Earnings	Aug 06 AMC	Avg Volume	559.04K	Price	6.93
SMA20	-7.37%	SMA50	-14.54%	SMA200	-41.91%	Trades		Volume	245,942	Change	-4.41%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-24	Downgrade	Jefferies	Buy → Hold	$20 → $8
Jul-31-24	Upgrade	B. Riley Securities	Neutral → Buy	$19 → $15
May-03-24	Downgrade	B. Riley Securities	Buy → Neutral	$22 → $19
Apr-04-24	Resumed	Jefferies	Buy	$17 → $21
Mar-13-24	Reiterated	Needham	Buy	$19 → $18
Aug-17-23	Initiated	Morgan Stanley	Equal-Weight	$16
Aug-10-23	Downgrade	Stephens	Overweight → Equal-Weight	$15
Jul-18-23	Downgrade	UBS	Buy → Neutral	$28 → $17
Jul-17-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jul-13-23	Downgrade	SVB Securities	Outperform → Market Perform	$30 → $10
Jan-19-22	Upgrade	ROTH Capital	Neutral → Buy	$90
Nov-05-21	Downgrade	ROTH Capital	Buy → Neutral	$78 → $90
Oct-19-21	Resumed	B. Riley Securities	Buy	$81
Jul-16-21	Initiated	BTIG Research	Buy	$80
Mar-15-21	Initiated	UBS	Buy	$84
Mar-02-21	Resumed	Needham	Buy	$73
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$54
Jan-08-20	Initiated	Stephens	Overweight	$21
Jul-01-19	Resumed	Needham	Buy	$22
Oct-10-18	Initiated	B. Riley FBR	Buy	$22

Show Previous Ratings

Oct-22-24 08:30AM	Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services (PR Newswire)
Oct-21-24 08:30AM	TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics (PR Newswire)
Oct-15-24 08:30AM	VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies (PR Newswire)
Oct-07-24 08:30AM	Cryoport Launches its IntegriCell Cryopreservation Solution with Opening of New Facility at its Houston Campus (PR Newswire)
Sep-25-24 08:30AM	SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices (PR Newswire)
05:28AM	Loading…
Sep-09-24 05:28AM	Should You Hold Cryoport (CYRX)? (Insider Monkey) -5.75%
Aug-19-24 03:27AM	Should You be Optimistic on the Growth Prospects of CryoPort (CYRX)? (Insider Monkey)
Aug-06-24 07:00PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Cryoport Reports Second Quarter 2024 Financial Results (PR Newswire)
04:05PM	Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes (PR Newswire)
Jul-23-24 08:30AM	Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024 (PR Newswire) -5.54%
Jul-12-24 02:46AM	CryoPort (CYRX) Moves 26.7% Higher: Will This Strength Last? (Zacks)
Jul-09-24 09:35AM	CryoPort (CYRX) Loses -43.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.51%
Jun-20-24 08:30AM	Cryoport and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies (PR Newswire)
May-17-24 02:33AM	Insider Sale: Director Richard Berman Sells 8,105 Shares of CryoPort Inc (CYRX) (GuruFocus.com) -7.39%
02:54PM	Loading…
May-08-24 02:54PM	Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Call Transcript (Insider Monkey) -19.51%
04:03AM	CryoPort Inc (CYRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-24 09:56PM	CYRX Stock Earnings: CryoPort Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:18PM	CryoPort Inc (CYRX) Q1 2024 Earnings: Revenue Declines Amid Challenges, Yet Maintains Full-Year ... (GuruFocus.com)
04:08PM	Cryoport Reports First Quarter 2024 Financial Results (PR Newswire)
May-03-24 10:12AM	B. Riley Downgrades Cryoport to Neutral From Buy, Adjusts Price Target to $19 From $22 (MT Newswires) -7.05%
06:41AM	B. Riley Downgrades Cryoport to Neutral From Buy, Cuts Price Target to $19 From $22 (MT Newswires)
Apr-30-24 08:30AM	Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024 (PR Newswire)
Apr-25-24 10:02AM	Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline (Zacks)
Mar-13-24 09:16AM	Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.90%
Mar-12-24 05:52PM	CryoPort Inc (CYRX) Reports Mixed Financial Results Amidst Global Challenges (GuruFocus.com)
05:30PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-27-24 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (PR Newswire) +5.95%
Feb-15-24 10:00AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:55AM	Loading…
Feb-13-24 09:55AM	Should You Buy CryoPort, Inc. (CYRX) After Golden Cross? (Zacks) -8.87%
Nov-27-23 08:30AM	Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services (PR Newswire)
Nov-21-23 03:26PM	Consultant's Insight: Cryoport expands its cold-chain supply chain capabilities (Air Cargo World)
Nov-16-23 08:30AM	Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express (PR Newswire)
Nov-09-23 05:23PM	Cryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.03%
Nov-08-23 06:05PM	CryoPort Inc (CYRX) Faces Economic Headwinds but Sees Growth in Key Segments (GuruFocus.com)
04:05PM	Cryoport Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-02-23 08:30AM	Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition (PR Newswire)
Oct-26-23 10:02AM	Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-25-23 08:30AM	Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023 (PR Newswire) -6.36%
Oct-12-23 08:30AM	Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF (PR Newswire)
Oct-10-23 08:30AM	Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies (PR Newswire) +5.19%
Oct-09-23 04:05PM	Be The Match BioTherapies and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies (PR Newswire)
Sep-14-23 08:30AM	Cryoport Receives 2023 IMAPAC Asia Pacific Cell & Gene Therapy Excellence Award (PR Newswire)
Aug-10-23 07:14AM	Cryoport (CYRX) Fell 28.1% in Q2 Despite Beating Earnings Expectations (Insider Monkey)
Aug-09-23 05:30PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-02-23 08:30AM	Cryoport to Report Second Quarter 2023 Financial Results on August 9, 2023 (PR Newswire)
Jul-31-23 08:53AM	Heres Why Cryoport (CYRX) Declined in Q2 (Insider Monkey)
Jul-23-23 08:17AM	Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
Jul-13-23 12:24PM	Trade Desk, MillerKnoll rise; CryoPort, Fastenal fall, Thursday, 7/13/2023 (AP Finance) -24.74%
11:17AM	Why Shares of Cryoport are Tumbling Thursday (Motley Fool)
Jul-12-23 04:05PM	Cryoport Announces Certain Preliminary Results for Second Quarter & Updates 2023 Revenue Expectations (PR Newswire)
12:56PM	Cryoport cuts FY guidance as Q2 revenue hurt by weaker demand; Shares sink (Investing.com)
Jun-29-23 08:39AM	IVFAustralia Selects Cryoport as Exclusive Supply Chain Solutions Provider (PR Newswire)
May-25-23 08:02AM	CryoPort (CYRX) Rose on Revenue Guidance (Insider Monkey)
May-12-23 07:15AM	Cryoport, Inc. (NASDAQ:CYRX) Screens Well But There Might Be A Catch (Simply Wall St.) -7.86%
May-04-23 06:05PM	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +13.71%
04:05PM	Cryoport Reports First Quarter 2023 Results (PR Newswire)
Apr-27-23 10:02AM	Will CryoPort, Inc. (CYRX) Report Negative Q1 Earnings? What You Should Know (Zacks)
08:30AM	Cryoport to Report First Quarter 2023 Financial Results on May 4, 2023 (PR Newswire)
Apr-25-23 08:30AM	Cryoport Signs New Supply Chain Solutions Agreement with Boston IVF to Support Reproductive Material Shipments Across the U.S. (PR Newswire) -6.78%
Apr-01-23 08:54AM	Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 94% Above Its Share Price (Simply Wall St.)
Mar-28-23 08:30AM	Cryoport Announces Multi-Year Agreement with Inception Fertility (PR Newswire)
Mar-16-23 03:46AM	Macroeconomic Headwinds Dragged Cryoport (CYRX) in Q4 (Insider Monkey) +8.28%
Mar-13-23 06:00AM	Cryoport Confirms No Financial Exposure to Silicon Valley Bank (PR Newswire)
Mar-08-23 01:15PM	Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company A Uniquely Positioned Ticker In The Weeds? (News Direct)
Feb-23-23 06:40PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +8.79%
04:05PM	Cryoport Reports Fourth Quarter and Full Year 2022 Results (PR Newswire)
Feb-15-23 08:30AM	Cryoport to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 (PR Newswire) +6.85%
Jan-29-23 07:31AM	When Will Cryoport, Inc. (NASDAQ:CYRX) Become Profitable? (Simply Wall St.)
Jan-26-23 10:55AM	Syneos Health (SYNH) Signs New Partnership With Cryoport (Zacks)
Jan-18-23 08:30AM	Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies (PR Newswire)
Dec-20-22 08:30AM	Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference (PR Newswire)
Dec-19-22 07:15AM	Cryoport (NASDAQ:CYRX) shareholders have earned a 15% CAGR over the last five years (Simply Wall St.) -5.30%
Nov-08-22 06:56AM	Cryoport Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-07-22 08:10PM	Time to Bottom Fish? 2 Strong Buy Stocks That Are Down 70% This Year (TipRanks)
05:03AM	Some Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Made A Major Cut To Next Year's Estimates (Simply Wall St.)
Nov-03-22 06:45PM	CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -32.05%
04:05PM	Cryoport Reports Results for the Third Quarter 2022 (PR Newswire)
Oct-27-22 08:30AM	Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022 (PR Newswire)
05:32AM	CryoPort, Inc. (CYRX) Stock Jumps 10.5%: Will It Continue to Soar? (Zacks)
Sep-08-22 08:30AM	Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services (PR Newswire)
Aug-08-22 02:42PM	Cryoport Stock Shows Market Leadership With Jump To 91 RS Rating (Investor's Business Daily) +6.83%
Aug-06-22 10:18AM	Cryoport, Inc.'s (NASDAQ:CYRX) Profit Outlook (Simply Wall St.)
Aug-05-22 09:55AM	Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect? (Zacks) +6.69%
Aug-04-22 07:15PM	CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Cryoport Reports Results for the Second Quarter 2022 (PR Newswire)
Jul-28-22 08:30AM	Cryoport to Report Second Quarter 2022 Financial Results on August 4, 2022 (PR Newswire)
Jul-01-22 08:57AM	Cryoport's (NASDAQ:CYRX) growing losses don't faze investors as the stock ascends 4.2% this past week (Simply Wall St.)
May-05-22 07:05PM	CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.97%
04:05PM	Cryoport Reports First Quarter 2022 Results (PR Newswire)
Apr-28-22 08:30AM	Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022 (PR Newswire)
Apr-20-22 05:59PM	CEO: Life sciences logistics firm eyes future growth in Houston, Central Texas markets (American City Business Journals) -6.48%
Apr-19-22 12:24PM	Cryoport, Cryogene growing Houston presence with new supply chain, logistics facility (American City Business Journals)
Apr-18-22 03:11PM	Cryoport pays nearly $7 million for France-based Cell&Co BioServices (American City Business Journals)
08:30AM	Cryoport Acquires Cell&Co BioServices (PR Newswire)
Mar-30-22 05:00PM	Cryoport's MVE Biological Solutions' New Prague Manufacturing Plant Returns to Full Production (PR Newswire)
Mar-11-22 03:40PM	Cryoport Authorizes $100 Million Repurchase Program (PR Newswire) -7.18%
Feb-24-22 06:30PM	CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hariri Robert J	Director	Aug 19 '24	Sale	9.46	1,000	9,465	23,061	Aug 26 07:11 PM
Hariri Robert J	Director	Aug 16 '24	Sale	9.00	1,000	9,000	23,561	Aug 20 05:28 PM
Hariri Robert J	Director	Aug 14 '24	Sale	8.40	1,000	8,395	24,561	Aug 20 05:28 PM
Mandalam Ramkumar	Director	Aug 02 '24	Option Exercise	5.04	4,167	21,002	60,199	Aug 06 08:00 PM
Mandalam Ramkumar	Director	Aug 02 '24	Sale	8.04	4,167	33,520	56,032	Aug 06 08:00 PM
RAMKUMAR MANDALAM	Director	Aug 02 '24	Proposed Sale	8.70	4,167	36,253		Aug 02 04:22 PM
BERMAN RICHARD J	Director	May 15 '24	Sale	13.41	8,105	108,693	100,000	May 16 05:30 PM
ZECCHINI EDWARD J	Chief Digital and Tech Officer	May 14 '24	Sale	13.37	3,443	46,042	60,051	May 15 07:28 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 25 '24	Sale	17.54	1,079	18,928	128,333	Mar 26 08:12 PM
SHELTON JERRELL	Chief Executive Officer	Mar 25 '24	Sale	17.54	2,631	46,154	692,182	Mar 26 08:09 PM
Sawicki Mark W	Chief Scientific Officer	Mar 25 '24	Sale	17.54	1,367	23,980	77,444	Mar 26 08:08 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 09 '24	Option Exercise	0.00	2,666	0	125,816	Mar 19 07:51 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 11 '24	Sale	16.35	1,119	18,298	124,697	Mar 19 07:51 PM
STEFANOVICH ROBERT	Chief Financial Officer	Mar 15 '24	Sale	15.43	1,035	15,972	123,662	Mar 19 07:51 PM
Sawicki Mark W	Chief Scientific Officer	Mar 09 '24	Option Exercise	0.00	2,666	0	75,791	Mar 19 07:50 PM
Sawicki Mark W	Chief Scientific Officer	Mar 11 '24	Sale	16.35	1,418	23,188	74,373	Mar 19 07:50 PM
Sawicki Mark W	Chief Scientific Officer	Mar 15 '24	Sale	15.43	1,312	20,247	73,061	Mar 19 07:50 PM
Mandalam Ramkumar	Director	Mar 15 '24	Option Exercise	5.40	8,334	45,004	46,404	Mar 19 07:49 PM
Mandalam Ramkumar	Director	Mar 15 '24	Sale	14.68	3,217	47,226	43,187	Mar 19 07:49 PM
BADDOUR LINDA	Director	Mar 15 '24	Option Exercise	0.00	1,111	0	21,690	Mar 19 07:48 PM
SHELTON JERRELL	President, CEO	Mar 15 '24	Option Exercise	4.80	100,000	480,000	749,253	Mar 19 07:48 PM
SHELTON JERRELL	President, CEO	Mar 09 '24	Option Exercise	0.00	8,250	0	640,674	Mar 19 07:48 PM
SHELTON JERRELL	President, CEO	Mar 15 '24	Sale	15.30	57,039	872,884	634,352	Mar 19 07:48 PM
SHELTON JERRELL	President, CEO	Mar 11 '24	Sale	16.35	3,723	60,880	636,951	Mar 19 07:48 PM
Hariri Robert J	Director	Dec 14 '23	Sale	16.89	800	13,512	12,716	Dec 18 07:19 PM
Hariri Robert J	Director	Dec 11 '23	Sale	15.50	1,000	15,500	13,516	Dec 13 06:02 PM

Open in Screener

BIVI

BioVie Inc

Oct 23 • 04:00PM ET

2.57

Dollar change -0.79
Percentage change -23.51	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY NBIX SAVA PRTA EQ ANVS ACAD AUTL AXSM

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-7.91	Insider Own	31.32%	Shs Outstand	6.19M	Perf Week	127.43%
Market Cap	20.51M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.48M	Perf Month	117.80%
Income	-33.01M	PEG	-	EPS next Q	-	Inst Own	5.90%	Short Float	6.99%	Perf Quarter	-41.93%
Sales	0.00M	P/S	-	EPS this Y	39.59%	Inst Trans	-27.67%	Short Ratio	0.10	Perf Half Y	-49.15%
Book/sh	2.51	P/B	1.03	EPS next Y	-	ROA	-106.51%	Short Interest	0.38M	Perf Year	-92.12%
Cash/sh	2.99	P/C	0.86	EPS next 5Y	-	ROE	-208.26%	52W Range	1.04 - 58.20	Perf YTD	-79.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.73%	ROI	-208.17%	52W High	-95.58%	Beta	1.11
Dividend TTM	-	Quick Ratio	2.57	Sales past 5Y	0.00%	Gross Margin	-	52W Low	147.02%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	2.57	EPS Y/Y TTM	49.34%	Oper. Margin	0.00%	RSI (14)	59.52	Volatility	95.67% 28.18%
Employees	14	Debt/Eq	0.39	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	68.09%	Payout	-	Rel Volume	9.22	Prev Close	3.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 10	Avg Volume	3.79M	Price	2.57
SMA20	73.24%	SMA50	13.12%	SMA200	-52.92%	Trades		Volume	34,965,331	Change	-23.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight	$7
Jan-15-21	Initiated	B. Riley Securities	Buy	$47

Today 03:24PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.51%
09:19AM	BioVie Announces Stock Offering and Private Placement (TipRanks)
08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 (GlobeNewswire)
Oct-22-24 04:01PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +27.76%
Oct-21-24 03:08PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +11.91%
08:00AM	Loading…
Oct-15-24 08:00AM	BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Oct-11-24 09:00AM	BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-01-24 08:00AM	BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Sep-25-24 04:05PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire) -7.50%
Sep-23-24 10:26PM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire) -57.86%
04:05PM	BioVie Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-16-24 08:00AM	BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Sep-03-24 08:00AM	BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Aug-27-24 08:45AM	BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-13-24 08:00AM	BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
07:30AM	Loading…
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -10.08%
Aug-08-24 06:00AM	BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease (GlobeNewswire) +13.30%
Aug-06-24 04:40PM	BioVie Inc. Announces Reverse Stock Split (GlobeNewswire) -21.40% -5.63%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-25-24 08:00AM	BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024 (GlobeNewswire) -5.32%
Jun-21-24 09:00AM	BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-20-24 08:00AM	BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress (GlobeNewswire)
Jun-12-24 08:24AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 (GlobeNewswire)
Jun-04-24 08:00AM	BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID (GlobeNewswire)
May-22-24 08:00AM	BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients (GlobeNewswire)
May-15-24 10:53AM	BIVI Stock Earnings: BioVie Beats EPS for Q3 2024 (InvestorPlace)
Apr-29-24 11:43AM	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID (MT Newswires)
08:00AM	BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID (GlobeNewswire)
Apr-25-24 08:00AM	BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints (GlobeNewswire)
Apr-18-24 08:00AM	BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation (GlobeNewswire)
09:00AM	Loading…
Apr-12-24 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Mar-26-24 10:30AM	Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation (PR Newswire) -6.17%
Mar-13-24 11:30AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie (PR Newswire) +6.93%
Mar-12-24 09:55AM	Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now (Zacks)
09:41AM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Mar-11-24 10:48AM	BioVie cuts 'most de-risked program,' will seek partners for phase-3 ready ascites program (FierceBiotech.com)
08:00AM	BioVie Announces Pipeline Update and Near-Term Clinical Priorities (GlobeNewswire)
Mar-06-24 06:21PM	BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire) -8.02% -10.25%
05:00PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire)
Mar-05-24 11:39AM	Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights BIVI (GlobeNewswire) -15.24%
Mar-04-24 05:16PM	BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline. (GlobeNewswire) -43.65%
08:51AM	Why Is BioVie (BIVI) Stock Down 41% Today? (InvestorPlace)
01:32AM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire)
Mar-01-24 04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.42%
04:58PM	BioVie Inc. Announces Proposed Public Offering of Common Stoc (GlobeNewswire)
10:57AM	Why Is BioVie (BIVI) Stock Up 100% Today? (InvestorPlace)
08:00AM	BioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2024 (GlobeNewswire)
Feb-23-24 04:49PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) -5.60%
12:30PM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
05:45AM	BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BIVI (PR Newswire)
Feb-19-24 01:12PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire)
Feb-09-24 03:40PM	Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered Hagens Berman (GlobeNewswire) +6.36%
Feb-07-24 01:00PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Feb-06-24 08:00AM	BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.83%
Jan-29-24 01:28PM	Investors Sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire) +12.07%
Jan-27-24 05:29AM	18 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-25-24 12:34PM	Investors sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Hagens Berman (GlobeNewswire)
Jan-24-24 11:30AM	BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-19-24 07:18PM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Jan-17-24 03:14PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys, Firm Investigating Possible Securities Law Violations (GlobeNewswire)
Jan-11-24 10:25AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Jan-05-24 02:08PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-29-23 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-25-23 11:15AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-22-23 09:00AM	Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-21-23 10:25AM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-18-23 02:32PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Dec-13-23 04:36PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire) -6.49%
Dec-11-23 09:35AM	BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-04-23 03:23PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire)
Nov-30-23 02:21PM	BioVie (BIVI) Plunges After Alzheimer's Drug Fails Phase 3 Due to Protocol Deviations at Trial Sites Hagens Berman (GlobeNewswire) -8.16%
10:20AM	BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data (Zacks)
Nov-29-23 11:38AM	Why Is BioVie (BIVI) Stock Down 63% Today? (InvestorPlace) -60.72%
09:34AM	BioVie blames protocol errors at trial sites for phase 3 Alzheimer's drug fail as stock craters (FierceBiotech.com)
08:00AM	BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease (GlobeNewswire)
Nov-13-23 08:00AM	BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2023 (GlobeNewswire)
Nov-10-23 09:00AM	DevvStream Holdings Inc. and BioVie Inc. Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE) +8.97%
Nov-02-23 08:00AM	BioVie to Participate in the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-30-23 01:00PM	BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial (News Direct) +21.32%
08:00AM	BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET (GlobeNewswire)
Oct-26-23 08:00AM	BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD The Liver Meeting 2023 (GlobeNewswire)
Oct-25-23 12:30PM	Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's Disease Patients (GlobeNewswire) -5.97%
Oct-19-23 10:00AM	Best Momentum Stocks to Buy for October 19th (Zacks) +7.10%
07:30AM	BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer's Disease at CTAD (GlobeNewswire)
Sep-26-23 08:00AM	BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease (GlobeNewswire) +8.62%
Sep-20-23 08:45AM	BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation (ACCESSWIRE)
Sep-19-23 08:00AM	BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -9.06%
Sep-12-23 02:10PM	BioVie chief social impact officer sees major need for Alzheimers support and research (News Direct)
Sep-11-23 08:00AM	BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimers Disease (GlobeNewswire)
Sep-07-23 08:00AM	BioVie Hosting Virtual KOL Event on NE3107 in Alzheimers Disease Today, September 7, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	BioVie to Host Virtual KOL Event on NE3107 in Alzheimers Disease on September 7, 2023 (GlobeNewswire) -6.61%
Aug-30-23 09:35AM	Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
09:35AM	Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI) (Zacks)
08:00AM	BioVie Presents Data for NE3107 at 2023 International Congress of Parkinsons Disease and Movement Disorders (GlobeNewswire)
Aug-24-23 09:35AM	Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI) (Zacks)
Aug-11-23 10:05AM	BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Jul-20-23 01:06PM	BioVie issues letter to shareholders; highlights latest update on NE3107 for Alzheimer's Disease (News Direct)
08:24AM	20 Countries with the Highest Rate of Dementia (Insider Monkey)

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORLIN STEVE	Director	Dec 01 '23	Sale	1.69	75,680	127,899	46,358	Dec 06 04:16 PM
DO CUONG V	President & CEO	Nov 30 '23	Buy	1.78	10,000	17,800	68,759	Dec 01 06:26 PM

CYRX

CryoPort Inc

BIVI

BioVie Inc

Upgrade your FINVIZ experience